9th MASH Drug Development Summit

The 9th MASH Drug Development Summit is the definitive meeting for pharma and biotech leaders advancing the next generation of therapies for MASH. With the approval of Rezdiffra signaling a new era, the race is on to deliver more effective, patient-centered treatments.

This year, dive into novel mechanisms of action, non-invasive biomarkers, and strategic combination and sequential therapies. Hear from experts at Eli Lilly, Pfizer, Takeda, Madrigal, Akero, 89 Bio, and more as they share cutting-edge research and clinical strategies targeting diverse patient populations.

Join 60+ MASH scientists and drug developers, gain critical insights, and build meaningful collaborations over 10+ hours of dedicated networking. Don’t miss the Pre-Conference Combination & Sequential Therapy Day for a focused deep dive into emerging treatment approaches.

Find out more now: https://ter.li/d9r0pm